These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9151838)

  • 41. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease.
    Lee SK; Potempa M; Kolli M; Özen A; Schiffer CA; Swanstrom R
    J Biol Chem; 2012 Apr; 287(16):13279-90. PubMed ID: 22334652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mapping and characterization of the N-terminal I domain of human immunodeficiency virus type 1 Pr55(Gag).
    Sandefur S; Smith RM; Varthakavi V; Spearman P
    J Virol; 2000 Aug; 74(16):7238-49. PubMed ID: 10906178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.
    Lavallée C; Yao XJ; Ladha A; Göttlinger H; Haseltine WA; Cohen EA
    J Virol; 1994 Mar; 68(3):1926-34. PubMed ID: 8107252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein.
    Tang C; Ndassa Y; Summers MF
    Nat Struct Biol; 2002 Jul; 9(7):537-43. PubMed ID: 12032547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological characterization of the gag gene products of bovine immunodeficiency virus.
    Battles JK; Hu MY; Rasmussen L; Tobin GJ; Gonda MA
    J Virol; 1992 Dec; 66(12):6868-77. PubMed ID: 1331499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing.
    Bardy M; Gay B; Pébernard S; Chazal N; Courcoul M; Vigne R; Decroly E; Boulanger P
    J Gen Virol; 2001 Nov; 82(Pt 11):2719-2733. PubMed ID: 11602784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure and architecture of immature and mature murine leukemia virus capsids.
    Qu K; Glass B; Doležal M; Schur FKM; Murciano B; Rein A; Rumlová M; Ruml T; Kräusslich HG; Briggs JAG
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11751-E11760. PubMed ID: 30478053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.
    Park J; Morrow CD
    J Virol; 1991 Sep; 65(9):5111-7. PubMed ID: 1870215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.
    Kaplan AH; Krogstad P; Kempf DJ; Norbeck DW; Swanstrom R
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2929-33. PubMed ID: 7695287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.
    McGettigan JP; Naper K; Orenstein J; Koser M; McKenna PM; Schnell MJ
    J Virol; 2003 Oct; 77(20):10889-99. PubMed ID: 14512539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional exchange of an oncoretrovirus and a lentivirus matrix protein.
    Deminie CA; Emerman M
    J Virol; 1994 Jul; 68(7):4442-9. PubMed ID: 8207817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
    Paxton W; Connor RI; Landau NR
    J Virol; 1993 Dec; 67(12):7229-37. PubMed ID: 8230445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assembly of HIV GAG-B-galactosidase fusion proteins into virus particles.
    Wang CT; Stegeman-Olsen J; Zhang Y; Barklis E
    Virology; 1994 May; 200(2):524-34. PubMed ID: 8178440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly.
    Martin JL; Mendonça LM; Marusinec R; Zuczek J; Angert I; Blower RJ; Mueller JD; Perilla JR; Zhang W; Mansky LM
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29695435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein.
    Cimarelli A; Luban J
    J Virol; 1999 Jul; 73(7):5388-401. PubMed ID: 10364286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.
    Chen N; Morag A; Almog N; Blumenzweig I; Dreazin O; Kotler M
    J Gen Virol; 2001 Mar; 82(Pt 3):581-590. PubMed ID: 11172099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
    DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
    Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles.
    Mak J; Jiang M; Wainberg MA; Hammarskjöld ML; Rekosh D; Kleiman L
    J Virol; 1994 Apr; 68(4):2065-72. PubMed ID: 7511167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
    Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
    Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.